Use of pamidronate in the management of acute cancer-related hypercalcemia in children

Med Pediatr Oncol. 1998 Feb;30(2):117-21. doi: 10.1002/(sici)1096-911x(199802)30:2<117::aid-mpo9>;2-l.


Purpose: To determine whether pamidronate is a safe and effective agent for the treatment of severe hypercalcemia of malignancy in children.

Materials and methods: A retrospective review of the charts of five children treated with pamidronate 1-2 mg/kg for severe, refractory hypercalcemia of malignancy. All children failed conventional therapy. Statistical analysis was done utilizing the two-tailed Student's t-test.

Results: All five children had complete resolution of their hypercalcemia in a predictable pattern within 24-48 hours. The average decrease in serum calcium was 1.63 mmol/L (6.54 mg/dl). (P < .01) The adverse effects were mild and transient, and consisted of hypocalcemia, hypophosphatemia, and hypomagnesemia.

Conclusions: Pamidronate at a dose of 1 mg/kg is a safe and effective treatment for severe, refractory hypercalcemia of malignancy in children.

MeSH terms

  • Acute Disease
  • Adolescent
  • Calcium / blood
  • Child
  • Child, Preschool
  • Diphosphonates / therapeutic use*
  • Female
  • Humans
  • Hypercalcemia / drug therapy*
  • Male
  • Neoplasms / complications*
  • Pamidronate
  • Retrospective Studies


  • Diphosphonates
  • Pamidronate
  • Calcium